The annual report coming later this month will have those details.
At the moment, us small shareholder are at the mercy of the serious hitters. Once the report is released, we will have a 'clearer' of the facts, rather than the myth!
Lefevre, i agree with your comment regarding trading term reduction of receivables. This was definitely on the immediate agenda when management changed hands. To what extent this reduced off balance sheet debt will be revealed soon.
The fact is, once the annual report reveals what is left, the tables will turn more into a story of growth and prosperity, rather than writedowns and nil returns to shareholders.
Pfizer had no choice but to go direct as most of their valuable patents expire in the mid term. But this will have little mid/long term effect on the industry since most seriously valuables patents will be expiring in the mid/long term anyhow.
The joint venture with aspen will provide a great foundation for future growth for sigma. Aspen indeed has a very competitive and extensive product and has the history to prove it manufactures high quality products very efficiently.
Sigma's distribution channel is worth a great deal of $$$$ to many players in the market! My personal view is that the distribution channel is worth far more than the manufacturing division, mainly due to the cost of production in Australia.
The books will be revealed to all shortly and this may allow the players sitting on the fence attack. Regardless, the writedowns and negative news is pretty much over with. Buy on the gloom. Classic story being unfolded here.
SIP Price at posting:
42.0¢ Sentiment: Buy Disclosure: Held
